Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke
Brief: FDA Authorizes Phase II Study For Natrunix In Rheumatoid Arthritis Patients
Brief: Xbiotech Announces First Subject Enrollment In Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke
Brief: Xbiotech Announces First Subject Enrollment In Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke
Brief: Xbiotech Inc - On February 10 Angela Hu, Assumed Role As Company's Principal Financial Officer And Principal Accounting Officer
Brief: XBiotech Announces Successful Completion Of Phase I Portion Of Pancreatic Cancer Study
Brief: XBiotech Announces French National Agency Approval For Cancer Treatment Study
Brief: Thorpe Mckenzie Reports 9.81% Passive Stake In Xbiotech Inc As Of December 31, 2021
Brief: Xbiotech Inks Clinical Manufacturing Deal
Brief: Xbiotech Executes Manufacturing Agreement With Janssen Research & Development
Brief: Xbiotech Announces First Patient Enrolled In Phase I Clinical Trial For Novel Arthritis Therapy Natrunix-Sq
Brief: FDA Approves XBiotech’s IND In Rheumatology
Brief: XBiotech Says FDA Approves Xbiotech’s IND In Rheumatology
Brief: XBiotech To Launch Novel Candidate Therapy For Stroke
Brief: XBiotech Announces First Patient Enrolled In Clinical Trial Evaluating XB2001
U.S. STOCKS ON THE MOVE-Tesla, Crypto stocks, Harley-Davidson, Manchester United